本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：300313 证券简称：*ST天山 公告编号：2025-026 新疆天山畜牧生物工程股份有限公司 关于参加新疆辖区上市公司 2025 年投资者 网上集体接待日活动的公告 二〇二五年五月十九日 为进一步加强与投资者的互动交流，新疆天山畜牧生物工程股份有限公司 （以下简称"公司"）将参加由新疆上市公司协会根据新疆证监局工作部署，联 合深圳市全景网络有限公司举办的"2025 年新疆辖区上市公司投资者网上集体 接待日活动"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP， 参与本次互动交流，活动时间为 2025 年 5 月 23 日（周五）15:00-17:30。届时 公司高管将在线就公司 2024 年度业绩、公司治理、发展战略、经营状况、融资 计划、股权激励和可持续发展等投资者关心的问题，与投资者进行沟通交流，欢 迎广大投资者踊跃参与。 特此公告。 新疆天山畜牧生物工程股份有限公 ...

Core Viewpoint - *ST Tianshan is facing significant financial pressure, leading to a strategic contraction in its upstream breeding business to ensure overall operational stability. The company plans to expand its breeding scale when financial conditions improve and market circumstances allow [1][5]. Company Summary - In April, *ST Tianshan sold 4 live cattle, generating revenue of 70,500 yuan, with month-on-month changes of -33.33% in sales volume and -20.89% in revenue, and year-on-year changes of -98.23% in sales volume and -95.68% in revenue [1]. - The company's main business is livestock farming, accounting for approximately 80% of its operations, primarily focusing on cattle breeding and beef cattle farming [1]. - In 2024, *ST Tianshan reported total operating revenue of 138 million yuan, a slight increase of 0.07% year-on-year, while net profit was -65.94 million yuan, representing a year-on-year increase in losses of 199.74% [5]. - For the first quarter of 2025, the company achieved operating revenue of 24.65 million yuan, a year-on-year increase of 40.5%, and a net profit of -4.96 million yuan, indicating a reduction in losses by 31.19% year-on-year [5]. Industry Summary - The beef cattle industry in China has faced challenges, including weakened external demand and insufficient domestic demand, leading to significant price declines for live cattle and beef products. The average monthly prices for beef and live cattle in 2024 dropped by 15% and 20%, respectively, reaching the lowest levels in five and ten years [2][4]. - The national beef cattle inventory at the end of 2024 was 10.047 million heads, showing a year-on-year decrease of 4.39% compared to 2023, despite an increase of 11.81% over the past 11 years [3]. - The overall scale of beef cattle farming in China is gradually improving, with a stable production capacity, but the economic benefits for farmers have significantly declined due to market downturns [2][4].

Core Viewpoint - *ST Tianshan is implementing a strategic contraction of its upstream breeding business due to significant financial pressure, as evidenced by a drastic decline in livestock sales and revenue [1][4]. Sales Performance - In April, *ST Tianshan sold only 4 head of livestock, generating a revenue of 70,500 CNY, which represents a month-on-month decline of 33.33% in sales volume and 20.89% in revenue [2][4]. - Year-on-year comparisons show a staggering drop of 98.23% in sales volume and 95.68% in revenue [2][4]. Financial Condition - For the year 2024, *ST Tianshan reported total revenue of 138 million CNY, a slight increase of 0.07% year-on-year, but a net loss of approximately 65.95 million CNY, which is a 199.74% increase in losses compared to the previous year [4]. - In the first quarter of 2025, the company achieved a revenue of approximately 24.65 million CNY, marking a year-on-year growth of 40.5%, while the net loss was reduced to about 4.96 million CNY, a decrease in losses by 31.19% [4]. Business Strategy - The company plans to strategically reduce its breeding operations to stabilize overall operations, with intentions to expand breeding scale when financial conditions improve [4]. - Approximately 80% of *ST Tianshan's main business is in the livestock industry, primarily focusing on cattle breeding and beef cattle farming [4].

Group 1 - Shengyi Electronics plans to repurchase shares with a total amount between 50 million and 100 million yuan, at a price not exceeding 43.02 yuan per share, for employee stock ownership plans [1] - Guoyao Modern's subsidiary has passed the consistency evaluation for the quality and efficacy of a generic drug, which is used for treating severe infections [1] - Tianhe Magnetic Materials' subsidiaries have obtained project filing notices for high-performance rare earth permanent magnet projects, with total investments of 100 million yuan and 50 million yuan respectively [1][2] Group 2 - Dream Lily intends to repurchase shares with an amount between 85 million and 170 million yuan, at a price not exceeding 10.90 yuan per share, supported by a loan commitment of up to 150 million yuan [3] - Weifu High-Tech has received a loan commitment of up to 135 million yuan from a financial institution for share repurchase [3] Group 3 - Lu'an Environmental Energy reported a coal sales volume of 4.51 million tons in April, a year-on-year increase of 17.75% [5] - *ST Tianshan reported a significant decline in livestock sales and revenue, with a revenue of 70,500 yuan in April, down 95.68% year-on-year [7] Group 4 - Feirongda announced a cash dividend of 0.38 yuan per 10 shares, with a total distribution of 21.9 million yuan [8] - Zhejiang Rongtai's shareholders and executives plan to reduce their holdings by up to 1.93% of the company's shares [9] Group 5 - Changhua Group's subsidiary won the land use rights for an industrial site in Ningbo for 27.05 million yuan, intended for manufacturing and related business [11] - Zejing Pharmaceutical's new drug application for a treatment for severe alopecia has been accepted by the regulatory authority [13][14] Group 6 - Hainan Mining plans to distribute a cash dividend of 0.8 yuan per 10 shares, totaling 1.59 billion yuan [15] - China Jushi plans to distribute a cash dividend of 0.24 yuan per share, totaling 9.61 billion yuan [16] Group 7 - Zhengzhong Design's subsidiary has obtained a utility model patent for an acrylic signage guide [18] - Rundu Co., Ltd. received approval for a veterinary drug product, which is intended for treating bacterial diseases in livestock [20] Group 8 - Emei Mountain A announced the resignation of its general manager due to work reasons [22] - Tonghua Dongbao's insulin injection has received a registration certificate in Nicaragua, allowing for sales in that market [23] Group 9 - Dizu Fashion's subsidiary has completed the registration of a private equity investment fund [24] - Ningbo Gaofa plans to increase capital by 60 million yuan in its subsidiary for operational needs [26] Group 10 - Haichuan Intelligent has obtained two utility model patents for material handling devices [27] - Newland's subsidiary signed a deep cooperation agreement with Alibaba Cloud for AI model applications [29] Group 11 - Rui Neng Technology's controlling shareholder plans to reduce its stake by up to 2.89% [30] - Guomai Culture intends to repurchase shares between 50 million and 100 million yuan for capital reduction [31] Group 12 - Shaanxi Construction won major construction projects totaling 7.88 billion yuan in April [32] - Hanyu Pharmaceutical signed a joint development agreement for a new peptide drug with a partner [34] Group 13 - Yunnan Copper is planning to acquire a 40% stake in Liangshan Mining, leading to a stock suspension [35] - Haizheng Pharmaceutical plans to repurchase shares between 50 million and 100 million yuan for employee stock ownership [36] Group 14 - Tianqiao Hoisting's controlling shareholder plans to increase its stake by 75 million to 150 million yuan [37] - Tiandi Online's controlling shareholder is transferring shares to introduce a strategic investor [38] Group 15 - Hongchang Technology plans to invest 15 million yuan in a joint venture with a partner [39] - Rabbit Baby's subsidiary is preparing for an IPO in Hong Kong [41] Group 16 - Wol Nuclear Materials is planning to issue H-shares for listing in Hong Kong [42] - Tangyuan Electric plans to raise up to 864 million yuan through a private placement for various projects [43] Group 17 - Tongrun Equipment's major shareholders plan to reduce their holdings by up to 2% [44] - Linzhou Heavy Machinery plans to raise up to 600 million yuan through a private placement [46] Group 18 - China Merchants Securities announced the resignation of its vice president [47] - Shangsheng Electronics plans to issue convertible bonds to raise up to 330 million yuan for various projects [48] Group 19 - Longda Co., Ltd.'s major shareholder plans to reduce its stake by up to 1% [49] - China Medical plans to acquire 100% of Jinsui Technology for 302 million yuan [50] Group 20 - Silek has signed a strategic cooperation agreement with a battery manufacturer [51] - Boyun New Materials' major shareholder plans to reduce its stake by up to 3% [53]

二、原因说明 鉴于公司现阶段面临较大的资金压力，为确保公司整体运营稳定，公司决定 对上游养殖业务实施战略性收缩调整。后续待公司资金状况改善并具备发展条件 时，公司将依据市场环境及公司实际情况，适时、适度地扩大养殖规模，推动业 务的持续发展。 证券代码：300313 证券简称：*ST天山 公告编号：2025-025 新疆天山畜牧生物工程股份有限公司 2025 年 4 月活畜销售情况简报 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、2025 年 4 月销售情况简报 新疆天山畜牧生物工程股份有限公司（以下简称"公司"）2025 年 4 月销 售活畜 4 头，销售收入 7.05 万元，环比变动分别为-33.33%、-20.89%；同比变 动分别为-98.23%、-95.68%。 新疆天山畜牧生物工程股份有限公司董事会 二〇二五年五月十三日 三、风险提示 （一）上述数据未经审计，可能与公司定期报告披露的数据存在差异，因此 上述数据仅作为阶段性数据供投资者参考。 （二）上述披露仅包含公司活畜销售情况，不含其它业务。 （三）《证券时报》《上海证券报》以及巨潮资讯网（ ...

Group 1: New Stock Offerings - ST Xinchao (600777) has a tender offer period from April 23, 2025, to May 22, 2025[1] - Puli Tui (300630) has 7 trading days remaining until the last trading day[1] - ST Zhongcheng (300208) reported severe abnormal fluctuations[1] Group 2: Trading Alerts - Jintai (300225) and other stocks are under observation for trading alerts due to abnormal fluctuations[1] - ST Yida (600608) and ST Huke (600608) are also flagged for trading alerts[1] - Multiple stocks including ST Shengda (002259) and ST Yushun (002289) are under scrutiny for trading activities[1] Group 3: Recent Announcements - Guofang Group (601086) and other companies have made recent announcements regarding their stock activities[1] - A total of 7 trading days remain for several stocks approaching their last trading day[1] - Various companies including ST Huada (603580) and ST Aiai (603580) have made recent disclosures[1]

公司截至2025年3月31日，*ST天山摊薄每股收益为-0.02元，在已披露的同业公司中排名第18。 2025年4月29日，*ST天山(300313.SZ)发布2025年一季报。 公司截至2025年3月31日，*ST天山营业总收入为2464.85万元，在已披露的同业公司中排名第21。截至2025年3月31日，*ST天山归母净利润为-495.92万元， 在已披露的同业公司中排名第16。截至2025年3月31日，*ST天山经营活动现金净流入为-714.59万元，在已披露的同业公司中排名第17，较去年同报告期经 营活动现金净流入减少1257.07万元，同比较去年同期下降231.73%。 公司截至2025年3月31日，*ST天山最新资产负债率为99.62%，在已披露的同业公司中排名第21，较上季度资产负债率增加1.91个百分点，较去年同期资产负 债率增加20.48个百分点。 公司截至2025年3月31日，*ST天山最新毛利率为11.43%，在已披露的同业公司中排名第14。 公司截至2025年3月31日，*ST天山最新总资产周转率为0.10次，在已披露的同业公司中排名第18。截至2025年3月31日，*ST天山最新存货 ...

Summary of Key Points Core Viewpoints - The report highlights the ongoing trend of stock suspensions due to delisting risk warnings across multiple companies, indicating a potential downturn in market confidence and stability [2][3][4]. Company Listings - Several companies are scheduled for initial public offerings (IPOs) on April 29, 2025, including Tai Li Technology (301595) and Ze Run New Energy (301636), which may attract investor interest [1]. - The report notes the specific dates for various IPO-related activities, such as inquiry periods and fund unfreezing dates, which are crucial for market participants [1]. Stock Suspension Announcements - Numerous companies, including Guohua Network Security (000004) and Nanhua Biology (000504), have announced stock suspensions due to delisting risk warnings, reflecting a significant concern regarding their financial health [2][3]. - The report lists a total of 30 companies facing stock suspensions on April 29, 2025, due to various risk warnings, which may impact investor sentiment and trading volumes [2][3][4]. Special Suspensions - Companies like *ST Xu Lan (000040) and *ST Gong Zhi (000584) are highlighted for potential termination of listings, indicating severe financial distress and regulatory scrutiny [4][5]. - The report emphasizes the importance of monitoring these companies as their situations evolve, which could present both risks and opportunities for investors [4][5].

新疆天山畜牧生物工程股份有限公司 新疆天山畜牧生物工程股份有限公司全体股东： 一、审计意见 我们审计了新疆天山畜牧生物工程股份有限公司（以下简称天山生物公司） 财务报表，包括 2024 年 12 月 31 日的合并及公司资产负债表，2024 年度的合并 及公司利润表、合并及公司现金流量表、合并及公司股东权益变动表以及财务 报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编制， 公允反映了天山生物公司 2024 年 12 月 31 日的合并及公司财务状况以及 2024 年 度的合并及公司经营成果和现金流量。 二、形成审计意见的基础 中兴财光华审会字（2025）第 213159 号 | 目录 | | --- | 审计报告 合并及公司资产负债表 1-2 合并及公司利润表 3 合并及公司现金流量表 4 合并及公司股东权益变动表 5-8 财务报表附注 9-104 审计报告 中兴财光华审会字(2025)第 213159 号 关键审计事项是我们根据职业判断，认为对本期财务报表审计最为重要的 事项。这些事项的应对以对财务报表整体进行审计并形成审计意见为背景，我 们不对这些事项单独发表意见。 除"与持续 ...

关于新疆天山畜牧生物工程股份有限公司 2024 年度财务报表无保留意见审计报告中与 持续经营相关的重大不确定性段和 强调事项段涉及事项的专项说明 中兴财光华审专字（2025）第 213089 号 关于新疆天山畜牧生物工程股份有限公司 2024 年度财务报表无保留意见审计报告中与持续经营相关 《中国注册会计师审计准则第 1324 号——持续经营》第二十一条规定，如 果运用持续经营假设是适当的，但存在重大不确定性，且财务报表对重大不确 定性已作出充分披露，注册会计师应当发表无保留意见，并在审计报告中增加 以"与持续经营相关的重大不确定性"为标题的单独部分，以提醒财务报表使用 者关注财务报表附注中与持续经营重大不确定性相关的事项或情况的披露；说 明这些事项或情况表明存在可能导致对被审计单位持续经营能力产生重大疑虑 的重大不确定性，并说明该事项并不影响发表的审计意见。 的重大不确定性段和强调事项段涉及事项的专项说明 中兴财光华审专字（2025）第 213089 号 新疆天山畜牧生物工程股份有限公司全体股东： 我们接受委托，审计了新疆天山畜牧生物工程股份有限公司（以下简称天 山生物公司）2024 年度财务报表，包括 2 ...